Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...

Orpha Labs AG today announced its compassionate use program to make ORL–101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...

BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency ...